Xing Zhou, Charters Thomas James
McMaster University, Infectious Diseases Division, Centre for Gene Therapeutics and Department of Pathology and Molecular Medicine, Hamilton, Ontario, L8N 3Z5, Canada.
Expert Rev Vaccines. 2007 Aug;6(4):539-46. doi: 10.1586/14760584.6.4.539.
The current tuberculosis (TB) epidemic continues to call for the development of effective vaccination strategies. The initial TB vaccine research effort mostly focused on the search for a vaccine that might be better than, and thus could replace, the current bacillus Calmette-Guérin (BCG) vaccine. It has increasingly been realized that BCG or an improved BCG will continue to be used as a prime TB vaccine and there is a need to develop effective boost vaccines that could enhance and prolong the protective immunity of BCG prime immunization. Mounting experimental evidence suggests that recombinant vaccines, including both recombinant protein and genetic vector vaccines, are effective in boosting immune activation and protection by BCG vaccination. This review will discuss recent advances and the authors' views in the development of there boost vaccines.
当前的结核病流行态势持续推动着有效疫苗接种策略的研发。最初的结核病疫苗研究工作主要集中在寻找一种可能比当前的卡介苗(BCG)更好、从而能够替代它的疫苗。人们越来越认识到,卡介苗或改进型卡介苗将继续用作主要的结核病疫苗,因此有必要研发有效的加强疫苗,以增强并延长卡介苗初次免疫接种所产生的保护性免疫。越来越多的实验证据表明,包括重组蛋白疫苗和基因载体疫苗在内的重组疫苗在增强卡介苗接种所引发的免疫激活和保护作用方面是有效的。本综述将讨论这些加强疫苗研发方面的最新进展以及作者的观点。